FOLFIRINOX versus Gemcitabine/nabPaclitaxel as First-line palliative Therapy in advanced Pancreatic Cancer: a Propensity-Score Analysis
Riedl, JM; Posch, F; Gantschnigg, A; Horvath, L; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A WIEN KLIN WOCHENSCHR. 2020; 132(SUPPL 2): 78-79.
Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Greil, R; Rischin, D; Harrington, KJ; Soulieres, D; Tahara, M; de Castro, G; Psyrri, A; Baste, N; Neupane, P; Bratland, A; Fuereder, T; Hughes, BGM; Mesia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Lin, J; Swaby, RF; Gumuscu, B; Burtness, B ANN ONCOL. 2020; 31: S660-S661.
TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia
Hartmann, TN; Szenes, E; Polcik, L; Decker, S; Haslauer, T; Pischeli, J; Kissel, S; Hopner, JP; Egle, A; Zaborsky, N; Dierks, C; Greil, R; Gattei, V; Harzschel, A ONCOL RES TREAT. 2020; 43(SUPPL 4): 70-70.
Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis
Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A ANN ONCOL. 2020; 31: S942-S942.
PHASE 1 STUDY OF AMG 160, A HALF-LIFE EXTENDED BITE (R) (BISPECIFIC T-CELL ENGAGER) THERAPY TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Dorff, T; Rettig, M; Machiels, JP; Lolkema, M; Autio, K; Greil, R; Rottey, S; Adra, N; Salvati, M; Poon, S; Tan, D; Jurida, G; Kouros-Mehr, H; Fizazi, K; Tran, B; Horvath, L J IMMUNOTHER CANCER. 2020; 8: A207-A208.
Changes in the time to neoadjuvant chemotherapy start over the past 10 years and correlation with outcome in early breast cancer patients
Hofer, S; De Pellegrin, L; Weiss, R; Zapf, K; Gampenrieder, SP; Hauser-Kronberger, C; Reitsamer, R; Greil, R; Rinnerthaler, G ONCOL RES TREAT. 2020; 43(SUPPL 4): 161-162.
Incidence, prediction and outcome of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of Gemcitabine/nab-Paclitxel or FOLFIRINOX
Schwarzenbacher, E; Moik, F; Horvath, L; Renneberg, F; Posch, F; Barth, D; Gantschnigg, A; Schaberl-Moser, R; Pichler, M; Stotz, M; Stoger, H; Ay, C; Greil, R; Gerger, A; Djanani, A; Schlick, K; Riedl, J ONCOL RES TREAT. 2020; 43(SUPPL 4): 214-214.
S-1 maintenance therapy in non-Asian patients with advanced, Her-2 negative esophagogastric adenocarcinoma – First results of the international MATEO trial initiated by the AIO
Haag, GM; Stocker, G; Lorenzen, S; Ettrich, TJ; Longo, F; Kiani, A; Venerito, M; Trojan, J; Mahlberg, RJC; Moosmann, N; Chibaudel, B; Kubicka, S; Greil, R; Daum, S; Geissler, M; Mann, J; Lordick, F ANN ONCOL. 2020; 31: S910-S910.
TRYbeCA-1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).
Hammel, P; Berardi, R; Creemers, GY; Cubillo, A; Van Cutsem, E; Greil, R; Macarulla, T; Metges, JP; Noel, MS; Nygren, P; Osterlund, PJ; Seufferlein, T; Wasan, HS; Gupta, A; Grummer, LM; Biswas-Baldwin, N; Kay, R; Youssoufian, H; El-Hariry, I; Hidalgo, M J CLIN ONCOL. 2020; 38(15):
Applicability of carboplatin containing neoadjuvant treatment regimen in triple negative early breast cancer patients – a single center experience
De Pellegrin, L; Hofer, S; Weiss, R; Zapf, K; Gampenrieder, SP; Hauser-Kronberger, C; Reitsamer, R; Greil, R; Rinnerthaler, G ONCOL RES TREAT. 2020; 43(SUPPL 4): 158-159.
